{"id":50910,"date":"2014-11-11T18:33:01","date_gmt":"2014-11-11T18:33:01","guid":{"rendered":"https:\/\/www.nationaldrugscreening.com\/?p=50910"},"modified":"2021-02-17T10:12:28","modified_gmt":"2021-02-17T15:12:28","slug":"oral-fluid-drug-testing-development-part","status":"publish","type":"post","link":"https:\/\/www.nationaldrugscreening.com\/blogs\/oral-fluid-drug-testing-development-part\/","title":{"rendered":"Will DOT Approve Oral Fluid Drug Testing Part \u2013 2"},"content":{"rendered":"\n

More on the development of oral fluid drug testing.<\/strong><\/p>\n\n\n\n

Click Here for Oral Fluid Drug Testing Development Part \u2013 1<\/strong><\/a><\/p>\n\n\n\n

The use of oral fluid<\/a><\/strong> as a specimen source for substance abuse testing moved ahead at the same pace from April 1997 to January 2006 as testing with the use of the other specimens, i.e., hair, sweat patch and on-site testing devices.\u00a0 After the rejection of the proposed Mandatory Guidelines in 2006, it became apparent that much more work would be needed to make the use of alternative specimens viable and forensically defensible, especially for Federal regulated workplace drug testing<\/strong><\/a>.<\/p>\n\n\n\n

In a November 25, 2008 update to the Mandatory Guidelines was this statement: \u201cWith regard to the use of alternative specimens including hair, oral fluid, and sweat patch specimens in Federal Workplace Drug Testing Programs, significant issues have been raised by Federal agencies during the review process which require further examination, and may require additional study and analysis.\u201d  What that statement meant was that more information and data had to be collected to meet the goal of allowing these alternative specimens to be used in Federal regulated workplaces and to be forensically defensible.  In the meantime, the drug testing industry was going down the path of using alternative specimens for non-Federal regulated workplaces.<\/p>\n\n\n\n

The data gathering for oral fluid did not progress much until August 2008.\u00a0 Data was presented to DTAB giving the results of 5 years of test results with oral fluid as the specimen source.\u00a0 The data was extracted from 650,000 analyzed specimens collected from January 1, 2003 to December 31, 2007.\u00a0 It is interesting to note over half of these specimens were collected in 2007.\u00a0 Out of the data collected for 650,000 specimens, 648,372 specimens were analyzed with a positive rate 4.3%.\u00a0 The MRO<\/a><\/strong> verification rate was almost 96% with most of the reversals due to prescribed use of opiates and amphetamines.\u00a0<\/p>\n\n\n\n

The following drugs were identified in this dataset and reported by the MRO service as verified positives:<\/p>\n\n\n\n

\n\n\n\n\n\n\n\n\n
\n

Drug\/Drug class<\/strong><\/p>\n<\/td>\n

\n

Percent Positive Rate<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Marijuana<\/p>\n<\/td>\n

\n

60.4%<\/p>\n<\/td>\n<\/tr>\n

\n

Cocaine<\/p>\n<\/td>\n

\n

24.1%<\/p>\n<\/td>\n<\/tr>\n

\n

Methamphetamine                            <\/p>\n<\/td>\n

\n

  6.4%<\/p>\n<\/td>\n<\/tr>\n

\n

Amphetamine<\/p>\n<\/td>\n

\n

  4.3%<\/p>\n<\/td>\n<\/tr>\n

\n

Opiates<\/p>\n<\/td>\n

\n

  3.9%<\/p>\n<\/td>\n<\/tr>\n

\n

PCP<\/p>\n<\/td>\n

\n

  0.5%<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n\n\n\n

It is interesting to note that this dataset showed the reversal rate for amphetamines was very similar for urine based drug testing.<\/p>\n\n\n\n

Further analysis of the data showed over 8,000 were rejected for testing as shown in the table shown below:<\/p>\n\n\n\n

\n\n\n\n\n\n
\n

Rejection Reason<\/strong><\/p>\n<\/td>\n

\n

Number of specimens Rejected<\/strong><\/p>\n<\/td>\n<\/tr>\n

\n

Insufficient specimen volume<\/p>\n<\/td>\n

\n

Over 4,000 specimens<\/p>\n<\/td>\n<\/tr>\n

\n

Specimen seal broken or tampered                                              <\/p>\n<\/td>\n

\n

Approximately 2,700 specimens<\/p>\n<\/td>\n<\/tr>\n

\n

Mismatched numbers on the specimen and CCF<\/p>\n<\/td>\n

\n

448 specimens<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n\n\n\n

There were 614 specimens with a report of being invalid.  483 specimens of these 614 specimens were identified as not having detectable amounts of IgG.  72 specimens exhibited interference with the GC\/MS analysis.  There were some specimens that were identified as QNS (Quantity Not Sufficient) and as a consequence, confirmatory analysis could not be performed.<\/p>\n\n\n\n

A comparison to urine based drug testing was performed with the positive rates were found to be comparable to non-regulated urine based drug testing.<\/p>\n\n\n\n

On September 28, 2008, there was a closed (not open to the public) meeting with the following oral fluid items being discussed:<\/p>\n\n\n\n

  1. Oral Fluid Issues; and<\/li>
  2. Oral Fluid Laboratory, Instrumented Initial Test Facility, Point of Collection Tests.<\/li><\/ol>\n\n\n\n

    All of these efforts were combined to facilitate a viable discussion for the use of oral fluid in workplace drug testing.<\/p>\n\n\n\n

    <\/p>\n\n\n\n

    Learn more about oral fluid drug testing<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

    More on the development of oral fluid drug testing. Click Here for Oral Fluid Drug Testing Development Part \u2013 1 The use of oral fluid as a specimen source for substance abuse testing moved ahead at the same pace from April 1997 to January 2006 as testing with the use of the other specimens, i.e., […]<\/p>\n","protected":false},"author":12,"featured_media":51849,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"50870,51101,51365,50862,50901,51541","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/50910"}],"collection":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/comments?post=50910"}],"version-history":[{"count":0,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/50910\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media\/51849"}],"wp:attachment":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media?parent=50910"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/categories?post=50910"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/tags?post=50910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}